

COVID-19 Results Briefing

European Union

July 1, 2021

This document contains summary information on the latest projections from the IHME model on COVID-19 in the European Union. The model was run on July 1, 2021, with data through June 29, 2021.

Daily reported cases and deaths continue to decline. The majority of the EU Member States have reported declines, but Cyprus, Portugal, and some regions in Spain have increasing transmission. These locations demonstrate that the Delta variant can lead to increases despite low seasonality and rising vaccination. The key question is whether the Delta variant surges will spread to the rest of the EU. A number of countries have low levels of the Delta variant. Whether we see surges depends on whether there is sufficient transmission in the community for the increased transmissibility and immune escape of the Delta variant to lead to a surge. Our model currently suggests we will not see major surges in the rest of the EU during the summer. In longer-range forecasts, we expect major surges later in the fall and winter. However, if the Delta variant is more transmissible than what we have estimated based on the Public Health England analyses of secondary attack rates, then surges in other countries in Europe are very possible. Increases in Israel, with high levels of Pfizer vaccination, demonstrate that increasing transmission is possible in many countries. Likewise, the surge in Scotland as well as the rest of the United Kingdom shows that dramatic increases in transmission are possible, despite moderately high levels of vaccination with AstraZeneca. Effective policy strategies for governments to consider during this period of uncertainty include a) taking every effort to reduce vaccine hesitancy and increase vaccination coverage; b) given the evidence that AstraZeneca, Johnson & Johnson, and other vaccines are less effective against the Delta variant than the mRNA vaccines, consider giving a dose of mRNA vaccine to those who have received the less effective vaccines; c) increase surveillance efforts, particularly genetic sequencing, so that if the Delta variant starts to surge it is identified quickly; and d) consider mask use even in the vaccinated and social distancing measures, if major surges take place.

Current situation

- Daily reported cases in the last week (through to June 25) decreased to 11,200 per day on average compared to 13,200 the week before (Figure 1).
- Reported deaths due to COVID-19 in the last week decreased to 180 per day on average compared to 280 the week before (Figure 2).
- Excess deaths due to COVID-19 in the last week decreased to 310 per day on average compared to 500 the week before (Figure 2). This makes COVID-19 the number 12 cause of death in the European Union this week (Table 1). **Estimated excess daily deaths due to COVID-19 were 1.7 times larger than the reported number of deaths.**

- No locations had daily reported COVID-19 death rates greater than 4 per million (Figure 3).
- No locations had daily rates of excess deaths due to COVID-19 greater than 4 per million (Figure 3).
- We estimated that 26% of people in the European Union have been infected as of June 29 (Figure 5).
- Effective R, computed using cases, hospitalizations, and deaths, is greater than 1 in Portugal, Cyprus, and some regions of Spain (Figure 6).
- The infection-detection rate in the European Union was close to 38% on June 29 (Figure 7).
- Based on the GISAID and various national databases, combined with our variant spread model, we estimate the current prevalence of variants of concern (Figure 8). We estimate that B.1.351 is circulating in eight countries, that B.1.617.2 is circulating in ten countries, and that P.1 is circulating in three countries.

Trends in drivers of transmission


- In contrast to North America, many mandates remain in place in the EU. The majority of EU Member States have mask mandates and gathering restrictions. Some mandates were lifted in France, Italy, and Lithuania.
- Mobility last week was 8% lower than the pre-COVID-19 baseline (Figure 10). Mobility was near baseline (within 10%) in 23 Member States. Mobility was lower than 30% of baseline in no locations.
- As of June 29, according to the Global COVID-19 Symptom Surveys and the US COVID-19 Symptom Surveys, 57% of people self-report that they always wore a mask when leaving their home, reflecting the fastest decline since June 2020 (Figure 12). Mask use was lower than 50% in Austria, Belgium, Bulgaria, Croatia, Czechia, Denmark, Estonia, Germany, Hungary, Lithuania, Malta, the Netherlands, Poland, Romania, Slovakia, Slovenia, and Sweden.
- There were 279 diagnostic tests per 100,000 people on June 29 (Figure 14).
- In the European Union, 74.8% of people say they would accept or would probably accept a vaccine for COVID-19. The fraction of the population open to receiving a COVID-19 vaccine ranges from 39% in Bulgaria to 95% in Spain (Figure 18).
- In our current reference scenario, we expect that 393 million people in the EU will be vaccinated with at least one dose by October 1 (Figure 19). **Taking into account vaccine efficacy, this means that nearly 65% of the adult population in the EU will have functional immunity by October 1.**

Projections

- In our **reference scenario**, which represents what we think is most likely to happen, our model projects 749,000 cumulative reported deaths due to COVID-19 on October 1. This represents 5,000 additional deaths from June 29 to October 1. Daily reported deaths are expected to decline until October 1, 2021 (Figure 20).
- Under our **reference scenario**, our model projects 1,303,000 cumulative excess deaths due to COVID-19 on October 1 (Figure 20).
- If **universal mask coverage (95%)** were attained in the next week, our model projects 1,200 fewer cumulative reported deaths compared to the reference scenario on October 1.
- Under our **worse scenario**, our model projects 752,000 cumulative reported deaths on October 1, an additional 3,400 deaths compared to our reference scenario. Daily reported deaths in the worse scenario are expected to decline until October 1, 2021 (Figure 20).
- By October 1, we project that 5,400 lives will be saved by the projected vaccine rollout. This does not include lives saved through vaccination that has already been delivered.
- Daily infections in the reference scenario are expected to stay low but increase slowly during August and September. Under the worse scenario, daily infections are expected to increase until mid-August and then decline until October 1, 2021 (Figure 21).
- Figure 22 compares our reference scenario forecasts to other publicly archived models. All the models included suggest daily deaths will decline at least until August and then either decline or stay constant.
- At some point from June through October 1, no Member States will have high or extreme stress on hospital beds (Figure 23). At some point from June through October 1, no Member States will have high or extreme stress on intensive care unit (ICU) capacity (Figure 24).

Model updates

Our modeling inclusion criteria for current local transmission of a variant were updated to account for locations with relatively few sequences, but for which all sequences were collected in the last few weeks. Specifically, we consider local transmission to have potentially occurred if a location has identified more than 50 sequences of a new variant in the previous six weeks. This rule essentially only applies to P.1 and B.1.617.2.

Figure 1. Reported daily COVID-19 cases**Table 1.** Ranking of excess deaths due to COVID-19 among the leading causes of mortality this week, assuming uniform deaths of non-COVID causes throughout the year

Cause name	Weekly deaths	Ranking
Ischemic heart disease	18,714	1
Stroke	10,303	2
Tracheal, bronchus, and lung cancer	6,216	3
Alzheimer's disease and other dementias	5,827	4
Chronic obstructive pulmonary disease	4,608	5
Colon and rectum cancer	4,100	6
Lower respiratory infections	3,503	7
Hypertensive heart disease	2,797	8
Chronic kidney disease	2,430	9
Breast cancer	2,213	10
COVID-19	2,170	12

Figure 2. Smoothed trend estimate of reported daily COVID-19 deaths (blue) and total daily COVID-19 deaths (orange).





Figure 3. Daily COVID-19 death rate per 1 million on June 29, 2021

A. Daily reported COVID-19 death rate per 1 million



B. Daily excess COVID-19 death rate per 1 million





Figure 4. Cumulative COVID-19 deaths per 100,000 on June 29, 2021

A. Reported cumulative COVID-19 deaths per 100,000



B. Excess cumulative COVID-19 deaths per 100,000




Figure 5. Estimated percent of the population infected with COVID-19 on June 29, 2021




Figure 6. Mean effective R on June 18, 2021. The estimate of effective R is based on the combined analysis of deaths, case reporting, and hospitalizations where available. Current reported cases reflect infections 11–13 days prior, so estimates of effective R can only be made for the recent past. Effective R less than 1 means that transmission should decline, all other things being held the same.




Figure 7. Percent of COVID-19 infections detected. This is estimated as the ratio of reported daily COVID-19 cases to estimated daily COVID-19 infections based on the SEIR disease transmission model. Due to measurement errors in cases and testing rates, the infection-detection rate can exceed 100% at particular points in time.






Figure 8. Estimated percent of circulating SARS-CoV-2 for primary variant families on June 29, 2021.


A. Estimated percent B.1.1.7 variant



B. Estimated percent B.1.351 variant



C. Estimated percent B.1.617 variant



D. Estimated percent P.1 variant





Figure 9. Infection-fatality ratio on June 29, 2021



Critical drivers

Table 2. Current mandate implementation




Figure 10. Trend in mobility as measured through smartphone app use compared to January 2020 baseline




Figure 11. Mobility level as measured through smartphone app use compared to January 2020 baseline (percent) on June 29, 2021




Figure 12. Trend in the proportion of the population reporting always wearing a mask when leaving home




Figure 13. Proportion of the population reporting always wearing a mask when leaving home on June 29, 2021




Figure 14. Trend in COVID-19 diagnostic tests per 100,000 people




Figure 15. COVID-19 diagnostic tests per 100,000 people on June 29, 2021




Figure 16. Increase in the risk of death due to pneumonia on February 1 compared to August 1




Table 3. Estimates of vaccine efficacy for specific vaccines used in the model at preventing disease and infection. The SEIR model uses variant-specific estimates of vaccine efficacy at preventing symptomatic disease and at preventing infection. We use data from clinical trials directly, where available, and make estimates otherwise. More information can be found on our [website](#).

Vaccine	Efficacy at preventing disease: D614G & B.1.1.7	Efficacy at preventing infection: D614G & B.1.1.7	Efficacy at preventing disease: B.1.351, B.1.617, & P.1	Efficacy at preventing infection: B.1.351, B.1.617, & P.1
AstraZeneca	74%	52%	53%	47%
CoronaVac	50%	44%	40%	35%
Covaxin	78%	69%	62%	55%
Janssen	72%	72%	64%	56%
Moderna	94%	89%	83%	79%
Novavax	89%	79%	73%	64%
Pfizer/BioNTech	91%	86%	81%	77%
Sinopharm	73%	65%	47%	41%
Sputnik-V	92%	81%	73%	65%
Tianjin	66%	58%	53%	47%
CanSino				
Other vaccines	75%	66%	60%	53%
Other vaccines (mRNA)	91%	86%	81%	77%

Figure 17. Trend in the estimated proportion of the adult (18+) population that have been vaccinated or would probably or definitely receive the COVID-19 vaccine if available.




Figure 18. This figure shows the estimated proportion of the adult (18+) population that has been vaccinated or would probably or definitely receive the COVID-19 vaccine if available.





Figure 19. Number of people who receive any vaccine and those who are effectively vaccinated and protected against disease, accounting for efficacy, loss to follow up for two-dose vaccines, partial immunity after one dose, and immunity after two doses.



Projections and scenarios

We produce three scenarios when projecting COVID-19. The **reference scenario** is our forecast of what we think is most likely to happen:

- Vaccines are distributed at the expected pace.
- Governments adapt their response by re-imposing social distancing mandates for 6 weeks whenever daily deaths reach 8 per million, unless a location has already spent at least 7 of the last 14 days with daily deaths above this rate and not yet re-imposed social distancing mandates. In this case, the scenario assumes that mandates are re-imposed when daily deaths reach 15 per million.
- Variants B.1.1.7 (first identified in the UK), B.1.351 (first identified in South Africa), and P1 (first identified in Brazil) continue to spread from locations with (a) more than 5 sequenced variants, and (b) reports of community transmission, to adjacent locations following the speed of variant scale-up observed in the regions of the United Kingdom.
- In one-quarter of those vaccinated, mobility increases toward pre-COVID-19 levels.


The **worse scenario** modifies the reference scenario assumptions in three ways:

- First, it assumes that variants B.1.351 or P.1 begin to spread within three weeks in adjacent locations that do not already have B.1.351 or P.1 community transmission.
- Second, it assumes that all those vaccinated increase their mobility toward pre-COVID-19 levels.
- Third, it assumes that among those vaccinated, mask use starts to decline exponentially one month after completed vaccination.

The **universal masks scenario** makes all the same assumptions as the reference scenario but also assumes 95% of the population wear masks in public in every location.

Figure 20. Daily COVID-19 deaths until October 01, 2021 for three scenarios

A. Reported daily COVID-19 death per 100,000



B. Excess daily COVID-19 deaths per 100,000




Figure 21. Daily COVID-19 infections until October 01, 2021 for three scenarios




Figure 22. Comparison of reference model projections with other COVID modeling groups. For this comparison, we are including projections of daily COVID-19 deaths from other modeling groups when available: Delphi from the Massachusetts Institute of Technology ([Delphi](#)), Imperial College London ([Imperial](#)), The Los Alamos National Laboratory ([LANL](#)), and the SI-KJalpha model from the University of Southern California ([SIKJalpha](#)). Daily deaths from other modeling groups are smoothed to remove inconsistencies with rounding. Regional values are aggregates from available locations in that region.




Figure 23. The estimated inpatient hospital usage is shown over time. The percent of hospital beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of beds occupied by COVID-19 patients. Less than 5% is considered *low stress*, 5-9% is considered *moderate stress*, 10-19% is considered *high stress*, and 20% or greater is considered *extreme stress*.





Figure 24. The estimated intensive care unit (ICU) usage is shown over time. The percent of ICU beds occupied by COVID-19 patients is color-coded based on observed quantiles of the maximum proportion of ICU beds occupied by COVID-19 patients. Less than 10% is considered *low stress*, 10-29% is considered *moderate stress*, 30-59% is considered *high stress*, and 60% or greater is considered *extreme stress*.



More information

Data sources:

Mask use and vaccine confidence data are from the [Global COVID-19 Symptom Survey](#) (this research is based on survey results from University of Maryland Social Data Science Center with Facebook's support) and the [US COVID-19 Symptom Survey](#) (this research is based on survey results from Carnegie Mellon University's Delphi Research Group with Facebook's support). Mask use data are also from [Premise](#), the Kaiser Family Foundation, and the [YouGov COVID-19 Behaviour Tracker](#) survey.

Genetic sequence and metadata are primarily from the GISAID Initiative. Further details available on the COVID-19 model [FAQ page](#).

A note of thanks:

We wish to warmly acknowledge the support of [these](#) and others who have made our COVID-19 estimation efforts possible.

More information:

For all COVID-19 resources at IHME, visit <http://www.healthdata.org/covid>.

Questions? Requests? Feedback? Please contact us at <https://www.healthdata.org/covid/contact-us>.